Innealta Capital’s MacroGenics MGNX Stock Holding History

Innealta Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-68	Closed	-$289	–	1064
2024 Q2	$289	Buy	+68	New	+$662	﹤0.01%	1556

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Innealta Capital's MGNX Position: Q3 2024 in Review

Innealta Capital sold out of MacroGenics (MGNX) in Q3 2024, closing a stake of 68 shares — an estimated $289 sold.

Innealta Capital first reported a position in MGNX in Q2 2024 and held it in 1 quarter. The position peaked at $289 in Q2 2024. 124 funds tracked by Wall St. Rank hold MGNX as of Q3 2024.

Innealta Capital reported no remaining MacroGenics position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 68 MacroGenics shares in Q3 2024, an estimated $289.
Innealta Capital first reported a position in MacroGenics in Q2 2024 and held it in 1 quarter.
Innealta Capital's MacroGenics position peaked at $289 in Q2 2024.
124 funds tracked by Wall St. Rank held MacroGenics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.